Anti-SARS-CoV Envelope antibody produced in rabbit

SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus′s life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

Anti-SARS-CoV Envelope antibody was raised against a peptide corresponding to 11 amino acids near the carboxy terminus of SARS-CoV Envelope protein. The immunogen is located within the last 50 amino acids of SARS-CoV Envelope.

SARS-CoV Envelope antibody can be used for the detection of SARS-CoV Envelope protein in ELISA. It will detect 5 ng of free peptide at 1 μg/mL.

Supplied in PBS containing 0.02% sodium azide.